Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
32 hedge funds and large institutions have $22.3M invested in Impel Pharmaceuticals Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 32 → 32 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
10% less capital invested
Capital invested by funds: $24.8M → $22.3M (-$2.49M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
McDonald Partners
Cleveland,
Ohio
|
+$12.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.49K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$864 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$165 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DCF Advisers
Greenwich,
Connecticut
|
-$121K |
| 2 |
JGC
J. Goldman & Co
New York
|
-$46.5K |
| 3 |
Millennium Management
New York
|
-$41K |
| 4 |
Renaissance Technologies
New York
|
-$17K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.39K |
IMPL Hedge Fund Activity: Q2 2023 in Review
32 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q2 2023, worth a combined $22.3M — down 10% from $24.8M a quarter earlier.
Fund positioning in IMPL was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was McDonald Partners, adding an estimated $12.9K. The largest seller was DCF Advisers, cutting an estimated $121K.
- 32 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $22.3M of Impel Pharmaceuticals Inc. Common Stock stock for Q2 2023, down 10% quarter-over-quarter.
- 2 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q2 2023 was McDonald Partners, an estimated $12.9K added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q2 2023 was DCF Advisers, an estimated $121K sold.
Based on aggregated 13F filings for Q2 2023.